How Orticumab Slows the Inflammation Process
Monday October 28, 2019
Orticumab is the first and only fully human monoclonal antibody of its kind targeting oxLDL to slow the inflammation process. Oxidized low density lipoprotein (oxLDL) is implicated in common, chronic conditions caused by inflammation such as cardiovascular disease, rheumatological diseases and cancer.
Orticumab has received strong scientific support and has been featured in several peer-reviewed scientific publications. By targeting oxLDL, Abcentra aims to bring new, safer and more effective treatment options to patients with inflammatory diseases.